Full course description
About this course
This program was developed to help oncology providers identify, evaluate, and manage patients at increased risk of hereditary cancer syndromes. The program was developed by the Michigan State Department of Health and Human Services and The Jackson Laboratory Clinical and Continuing Education Program with funding from the Centers for Disease Control and Prevention.
Genetic testing is becoming increasingly accessible for patients as the list of clinical indications and number of genes are growing, and the cost of testing is decreasing. Identifying a patient with an underlying genetic variant associated with cancer can impact his or her treatment options, long-term management approach, and risks for other cancer. In addition, there are implications for close family members. While genetic testing can provide important clinical information for decision-making, there are benefits, limitations, and risks. This program focuses on developing skills and knowledge to identify those patients most appropriate for genetic testing, choosing the right test, and using the results to develop a management plan.
Already enrolled? Access the course here.
Want to enroll? The course has been updated and moved. You can enroll here:
Publication Date: 10/31/2019
Expiration Date: 10/14/2021
Upon completion of this educational activity, the learner will be able to:
- Determine if a patient is a candidate for cancer genetic testing
- Deliver pre-testing counseling appropriate to the patient
- Select the best genetic test for the patient
- Interpret genetic testing results
- Identify patient management based on genetic testing results
This activity is designed to meet the educational needs of practicing clinicians who work with cancer patients.
Accreditation and Credit Designation Statement
Wayne State University designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Kate Reed, MPH, ScM, CGC, Director, Clinical and Continuing Education, The Jackson Laboratory
Linda Steinmark, MS, LCGC, Program Manager, Clinical and Continuing Education, The Jackson Laboratory
Emily Edelman, MS, CGC, Associate Director, Clinical and Continuing Education, The Jackson Laboratory
Therese Ingram Nissen, MA, Senior Instructional Designer/Technologist, The Jackson Laboratory
Angela Trepanier, MS, CGC, Director, Genetic Counseling Graduate Program, Associate Professor (Clinician Educator), Center for Molecular Medicine and Genetics, Wayne State University School of Medicine
Unless noted, no individuals in control of content reported a conflict of interest.
Fehniger, J., Lin, F., Beattie, M., Joseph, G., & Kaplan, C. (2013). Family communication of BRCA 1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. Journal of Genetic Counseling, 22(5), 603–612. doi:10.1007/s10897‐013‐9592‐4.
Gupta S, Provenzale D, Llor X, Halverson AL, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019 Sep 1;17(9):1032-1041.
Jain, R., Savage, M. J., Forman, A. D., Mukherji, R., & Hall, M. J. (2016). The relevance of hereditary cancer risks to precision oncology: what should providers consider when conducting tumor genomic profiling? Journal of the National Comprehensive Cancer Network, 14(6), 795–806.
Kurian AW, Ward KC, Hamilton AS, et al. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol. 2018; 4(8):1066-.
Lundy MG, Forman A, Valverde K, Kessler L. An Investigation of Genetic Counselors’ Testing Recommendations: Pedigree Analysis and the Use of Multiplex Breast Cancer Panel Testing. J Genet Counsel. 2014; 23(4):618-632.
National Comprehensive Cancer Network (2019): Genetic/Familial High Risk Assessment: Breast and Ovarian, Version 3.2019. Accessed 10/30/2019. (free registration required for access)
Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012 Apr;21(2):151-61.
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., et al. (2015). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 33(31), 3660–3667.
Szender JB, Kaur J, Clayback K, et al. Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer. 2018; 28(1):26-33.
Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; 13(9):581-588.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA -Related Cancer. JAMA. 2019; 322(7):652-.
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher
For best performance in a mobile environment, please download the Canvas Mobile App for IOS and Android.
Should you have technical questions or questions regarding the content of the activity, please email Clinical and Continuing Education at the Jackson Laboratory.
All information in Hereditary Cancer Syndromes: Are Your Patients at Risk? is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Hereditary Cancer Syndromes: Are Your Patients at Risk?. Reliance on any information in this program is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Hereditary Cancer Syndromes: Are Your Patients at Risk?